InterCure Ltd. (NASDAQ:INCR) Short Interest Update

InterCure Ltd. (NASDAQ:INCR) was the target of a large increase in short interest during the month of June. As of June 15th, there was short interest totaling 47,234 shares, an increase of 72.6% from the May 31st total of 27,374 shares. Based on an average daily trading volume, of 74,696 shares, the short-interest ratio is currently 0.6 days. Currently, 0.1% of the shares of the company are sold short.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings reissued a “sell (e+)” rating on shares of InterCure in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock presently has an average rating of “Sell”.

InterCure Trading Down 4.4%

InterCure stock traded down $0.05 during midday trading on Thursday, reaching $1.08. The stock had a trading volume of 33,072 shares, compared to its average volume of 54,574. The company has a quick ratio of 0.97, a current ratio of 1.48 and a debt-to-equity ratio of 0.20. The firm has a market cap of $59.05 million, a price-to-earnings ratio of 36.00 and a beta of 1.39. InterCure has a 52-week low of $0.68 and a 52-week high of $1.77. The company has a fifty day moving average of $0.93 and a 200 day moving average of $0.92.

InterCure (NASDAQ:INCR) last released its earnings results on Thursday, April 30th. The company reported ($0.10) earnings per share for the quarter. The business had revenue of $23.15 million during the quarter.

About InterCure

InterCure Ltd is an Israel-based medical cannabis company publicly listed on the Nasdaq Capital Market under the ticker INCR. The company’s operations span the entire value chain of medical cannabis, from the development of proprietary seed strains and controlled cultivation in a GMP-compliant facility to laboratory testing, cannabinoid extraction and formulation. InterCure serves licensed pharmacies and clinics within Israel and adheres to the regulatory framework established by the Israeli Ministry of Health.

Founded in 2013, InterCure has built a vertically integrated platform that supports both patient care and research initiatives.